

14 December 2022

Dear colleague

I am writing to highlight recent Pharmacogenomic additions to the [National Genomic Test Directory \(NGTD\)](#) for cancer which include *TPMT* and *NUDT15* genotyping for 6-mercaptopurine (6-MP) dosing in acute lymphoblastic leukaemia (ALL).

Should *TPMT* and *NUDT15* testing be required then please send a peripheral blood sample (5ml in EDTA) and a completed GMS test [request form](#) specifying *TPMT*/*NUDT15* (NGTD reference M91.80 and M91.81 respectively) to the [Bristol Genetics Laboratory, North Bristol NHS Trust, Pathology Building, Southmead Hospital, Southmead Road, Westbury-On-Trym, Bristol BS10 5NB](#). The target turnaround time for this test is 14 days from sample receipt. For further information on test requesting please contact nbn-tr.SWGLHcancer@nhs.net.

This update reflects well established practice in the treatment of childhood Acute Lymphoblastic Leukaemia (ALL), most recently as part of the ALLTogether protocol. Adult dosing guidance is expected to be published via the UK SACT Board website (uksactboard.org/publications) in January 2023. In the interim, the national ALL adult MDT can provide advice on the management of adult patients with variants.

East Genomic Laboratory Hub